FineMark National Bank & Trust lifted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,425 shares of the medical research company's stock after purchasing an additional 1,243 shares during the period. FineMark National Bank & Trust's holdings in Amgen were worth $6,539,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Braun Bostich & Associates Inc. purchased a new position in Amgen in the 1st quarter valued at approximately $113,000. WealthTrust Fairport LLC purchased a new position in Amgen in the 1st quarter valued at approximately $121,000. Cornerstone Advisors Inc. grew its stake in Amgen by 76.5% in the 1st quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company's stock valued at $124,000 after buying an additional 316 shares in the last quarter. Gables Capital Management Inc. purchased a new position in Amgen in the 1st quarter valued at approximately $174,000. Finally, Mount Yale Investment Advisors LLC purchased a new position in Amgen in the 1st quarter valued at approximately $181,000. Institutional investors and hedge funds own 80.04% of the company's stock. Get Amgen alerts:
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Monday, July 16th. The shares were sold at an average price of $195.71, for a total transaction of $298,457.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Insiders own 0.27% of the company's stock.
AMGN opened at $196.44 on Friday. The firm has a market cap of $125.84 billion, a PE ratio of 15.62, a PEG ratio of 1.90 and a beta of 1.36. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03. Amgen, Inc. has a one year low of $163.31 and a one year high of $201.23.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, beating analysts' consensus estimates of $3.52 by $0.31. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The business's revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the business earned $3.27 EPS. sell-side analysts forecast that Amgen, Inc. will post 13.95 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 7th. Stockholders of record on Friday, August 17th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Thursday, August 16th. Amgen's dividend payout ratio is currently 41.97%.
A number of research analysts recently weighed in on AMGN shares. Cann reiterated a "buy" rating and issued a $224.00 price objective on shares of Amgen in a research note on Monday, July 30th. BidaskClub upgraded shares of Amgen from a "sell" rating to a "hold" rating in a research note on Friday, May 25th. Mizuho set a $200.00 price objective on shares of Amgen and gave the company a "buy" rating in a research note on Tuesday, May 15th. Goldman Sachs Group reiterated a "buy" rating and issued a $228.00 price objective on shares of Amgen in a research note on Friday, July 27th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $200.00 price objective on shares of Amgen in a research note on Monday, July 16th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of "Hold" and a consensus target price of $202.76.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: Technical Analysis
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN). Amgen Amge